Resilia Pharmaceuticals has been granted the rights to manufacture, commercialize and sell Solace™ Eczema Cream, a medical device, as an OTC (over the counter) product in the United States. Signing the agreement with Pelle Ventures, the deal will make the cream more widely accessible for customers with eczema in the US, without the need for a prescription. Designed to help mitigate eczema flares, the Solace Eczema Cream uses the body’s natural cholesterol, fatty acids, and ceramides present in the skin, as well as palmitamide MEA (PEA), a naturally produced fatty acid that relieves itchy, dry skin from eczema. The Solace Cream is now mostly sold on Amazon, with plans to extend its promotion on the platform.
Read more here.
More on: Health Healthcare News Regulatory